Bouchal Jan Ph.D., Assoc. Prof.

Journals

FEIERSINGER, G., K. TRATTNIG, P. LEITNER, F. GUGGENBERGER, A. OBERHUBER, S. PEER, M. HERMANN, I. SKVORTSOVA, J. VRBKOVÁ, J. BOUCHAL, Z. CULIG, F. SANTER
Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells. Molecular Oncology. 2018, 12(4), 561-576, ISSN: 1574-7891, PMID: 29465803,
VONDALOVA BLANAROVA, O., B. SAFARIKOVA, J. HERUDKOVA, M. KRKOSKA, S. TOMANKOVA, Z. KAHOUNOVA, L. ANDERA, J. BOUCHAL, G. KHARAISHVILI, M. KRAL, M. SOVA, A. KOZUBIK, A. HYRSLOVA VACULOVA
Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10. Plos One. 2017, 12(11), e0188584, ISSN: 1932-6203, PMID: 29182622,  PDF.
JORDA, R., Z. BUCKOVA, E. ŘEZNÍČKOVÁ, J. BOUCHAL, V. KRYŠTOF
Selective inhibition reveals cyclin-dependent kinase 2 as another kinase that phosphorylates the androgen receptor at serine 81. Biochimica et Biophysica Acta. 2018, 1865(2), 354-363, ISSN: 0006-3002, PMID: 29157894,  PDF.